S&P Global Total Cost of Revenue increased by 5.6% to $1.24B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 7.1%, from $1.15B to $1.24B. Over 4 years (FY 2021 to FY 2025), Total Cost of Revenue shows an upward trend with a 20.2% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $533.00M | $543.00M | $582.00M | $749.00M | $1.01B | $989.00M | $1.01B | $1.09B | $1.03B | $995.00M | $1.03B | $1.11B | $1.08B | $1.07B | $1.11B | $1.15B | $1.12B | $1.12B | $1.17B | $1.24B |
| QoQ Change | — | +1.9% | +7.2% | +28.7% | +34.4% | -1.8% | +1.9% | +7.9% | -5.7% | -3.0% | +3.7% | +7.7% | -3.0% | -1.2% | +3.9% | +4.2% | -2.9% | +0.2% | +4.4% | +5.6% |
| YoY Change | — | — | — | — | +88.9% | +82.1% | +73.2% | +45.3% | +1.9% | +0.6% | +2.4% | +2.1% | +5.1% | +7.0% | +7.3% | +3.8% | +3.8% | +5.3% | +5.7% | +7.1% |